×
Amarin Total Liabilities 2010-2025 | AMRN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Amarin total liabilities from 2010 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
View More
Amarin Total Liabilities 2010-2025 | AMRN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Amarin total liabilities from 2010 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$245.4B
Amgen (AMGN)
$157.5B
Gilead Sciences (GILD)
$146.4B
Vertex Pharmaceuticals (VRTX)
$100B
Bristol Myers Squibb (BMY)
$98.1B
CSL (CSLLY)
$85.5B
GSK (GSK)
$79.6B
Regeneron Pharmaceuticals (REGN)
$60.8B
Alnylam Pharmaceuticals (ALNY)
$59.9B
Argenex SE (ARGX)
$40.5B
BioNTech SE (BNTX)
$27.1B
Insmed (INSM)
$26.9B
Royalty Pharma (RPRX)
$20.9B
Biogen (BIIB)
$19.9B
Incyte (INCY)
$16.6B
Illumina (ILMN)
$15.5B
Genmab (GNMSF)
$15.3B
Genmab (GMAB)
$15B
Ascendis Pharma (ASND)
$11.9B
BioMarin Pharmaceutical (BMRN)
$11B
Moderna (MRNA)
$10.9B
QIAGEN (QGEN)
$10.8B
Swedish Orphan Biovitrum (BIOVF)
$10.3B
Exelixis (EXEL)
$10.2B
Verona Pharma American Depositary Share (VRNA)
$9B
Exact Sciences (EXAS)
$8.5B
Bio-Techne Corp (TECH)
$8.4B
Blueprint Medicines (BPMC)
$8.3B
Halozyme Therapeutics (HALO)
$8.1B
Roivant Sciences (ROIV)
$8B